Intimation of Book Closure date July 24, 2025, to July 31, 2025 (both days inclusive)
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India Ltd's board, at its May 9, 2025 meeting, approved audited results for FY25 showing net profit of Rs 1,009 million, up 18% from Rs 851.9 million in FY24. Revenue from operations rose to Rs 3,562.7 million from Rs 3,350.7 million, while EPS improved to Rs 40.87 from Rs 34.50. The board recommended a final dividend of Rs 25 per share (on face value of Rs 5), unchanged from FY24, subject to shareholder approval at the 77th AGM on July 31, 2025. The register of members will be closed from July 24 to July 31, 2025 to determine dividend eligibility. The board also approved re-appointment of Mr. Sanker Parameswaran as Independent Director for a second 5-year term and appointed M K Saraf & Associates LLP as Secretarial Auditors.
Strong profit growth and steady dividend payout signal financial stability, though the unchanged dividend amount (vs FY24) may limit excitement. Investors buying shares before July 23, 2025 record date eligibility window will receive the Rs 25 dividend if approved at the AGM.